Descriptive analysis and prognostic factors in cats with myeloma‐related disorders: A multicenter retrospective study of 50 cases

• DOI: 10.1111/jvim.17051
• Publication Date: 2024-03-22T13:55:05Z
• Authors: Lorris Lecot; Isabelle Desmas‐B...; Sarah Benjamin; Pauline De Fornel; Frédérique Ponce; Matthew Kornya; Loïc Desquilbet; Claire Beaudu‐Lange; Catherine Ibisch; David Sayag; Ghita Benchekroun; Jérémy Béguin
• Keywords: Prednisolone; Plasmacytosis; Melphalan; Chlorambucil

Abstract Background Myeloma‐related disorders (MRDs) are rare and poorly documented neoplasms of cats. Hypothesis/Objectives To describe clinical, clinicopathologic, imaging findings, response to treatment, survival time identify factors associated with shorter outcomes in cats MRD. Animals Fifty a diagnosis Methods Cats paraproteinemia confirmed by serum protein electrophoresis (SPE) either intramedullary plasmacytosis >10%, marked cytonuclear atypia that ranged between 5% 10%, or cytologically histologically visceral infiltration were retrospectively included from several veterinary referral centers. Results Bone marrow splenic hepatic involvement present 17/27 (63%), 36/42 (86%), 27/38 (71%), respectively. Anemia was reported 33/49 (67%) thrombocytopenia 16/47 (34%). Some the treatments received melphalan prednisolone (n = 19), cyclophosphamide 10), chlorambucil 4), other 4). The overall rates melphalan, cyclophosphamide, combination 87%, 90%, 100%, Adverse events occurred 65% 23% cats, Median 122 days (range, 0‐1403) not significantly chemotherapy protocol. (hazard ratio [HR], 3.1; 95% confidence interval [CI], 1.0‐9.8) (HR, 2.7; CI, 1.2‐6.0) risk for survival. Conclusions Clinical Importance Our study guarded prognosis MRD identified times.